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The translation of laboratory innovations into clinical tools is dependent upon the develop-
ment of regulatory arrangements designed to ensure that the new technology will be used
reliably and consistently. A case study of a key post-genomic technology, gene chips or mi-
croarrays, exemplifies this claim. The number of microarray publications and patents has in-
creased exponentially during the last decade and diagnostic microarray tests already are
making their way into the clinic. Yet starting in the mid-1990s, scientific journals were overrun
with criticism concerning the ambiguities involved in interpreting most of the assumptions of
a microarray experiment. Questions concerning platform comparability and statistical calcu-
lations were and continue to be raised, in spite of the emergence by 2001 of an initial set of
standards concerning several components of a microarray experiment. This article probes
the history and ongoing efforts aimed at turning microarray experimentation into a viable,
meaningful, and consensual technology by focusing on two related elements:
1) The history of the development of the Microarray Gene Expression Data Society (MGED),
a remarkable bottom-up initiative that brings together different kinds of specialists from ac-
ademic, commercial, and hybrid settings to produce, maintain, and update microarray stan-
dards; and
2) The unusual mix of skills and expertise involved in the development and use of microar-
rays. The production, accumulation, storage, and mining of microarray data remain multi-
skilled endeavors bridging together different types of scientists who embody a diversity of
scientific traditions. Beyond standardization, the interfacing of these different skills has be-
come a key issue for further development of the field.
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INTRODUCTION
If asked what the term “science”
evokes, most people likely will reply “in-
vention” and “discovery,” certainly not
“standard-setting activities,” the latter being
most often associated with industry or even
boring, repetitive tasks. And yet, as many
contributors to the field of Science & Tech-
nology Studies have shown, standards are a
sine qua non of modern science. For one
thing, without scientific instruments, there
would be no experimental practice, and,
most importantly, the nature of knowledge
itself would be affected [1].Amachine as an
isolated entity does not produce meaningful
results, and debates about the factual status
of a given result hinge upon successful
claims about the reproducibility of the ex-
periment that produces it, which in turn de-
pends on establishing equivalences between
the instruments and research materials used
in different settings [2]. Much of modern bi-
ology and medicine, for instance, is predi-
cated upon the existence of standardized
mice [3,4].
In the last 10 to 15 years, standards and
other forms of regulation have ranked high
on the research agenda of sociologists and
historians of science. O’Connell, for in-
stance, convincingly has shown that labor-
intensive metrological practices underlie the
universality of scientific and technical
claims, and Mallard has further explored the
diversity and heterogeneity of metrological
networks [5,6,7]. In both cases, the authors
focused on physical entities for which “ab-
solute standards” can, at least in principle,
be defined. The situation is more complex
in biomedicine, where no absolute or pre-set
standards exist for, say, blood cells: In this
domain, metrology and standardization are
based on the degree of consensus regarding
samples analyzed in different laboratories
[8]. In other words, relative standards and
consistency of measurements, rather than
the search for a “true value,” are the rule of
the game. As forcefully argued by French
philosopher Georges Canguilhem, physio-
logical norms are ultimately dependent on
the environment and, thus, cannot be taken
as stand-alone, external standards. As a re-
sult, normalization does not presuppose a
norm; instead, norms are the result of nor-
malization processes [9].As we will discuss
in this article, a relatively novel situation
arises from the fact that the technologies of
contemporary biomedicine are increasingly
defined by a combination of computerized
instruments and molecular entities such as
genes and enzymes. Ideally, the standard-
setting activities that target, using different
assumptions and approaches, the engineer-
ing and biological components of a given
technology should be articulated or at least
aligned, but this is not necessarily the case.
Standards come in different forms and
are enforced and utilized for different pur-
poses.According to a typology proposed by
two medical sociologists, design standards
define the elements of complex systems of
action and allow them to function; termino-
logical standards fix the terms used to clas-
sify and describe phenomena in order to
achieve comparability among them; per-
formance standards define outcomes or re-
sults acceptable in particular situations; and
finally, procedural standards that depend on
the existence of the former three types of
standards specify the actions or protocols
that must be followed in given situations
[10]. While this typology of biomedical
standards is certainly useful, we should con-
textualize it by asking whether and how the
transformation of biomedical research over
the last 50 years, in particular the develop-
ment of molecular biology and, most re-
cently, genomics, has affected processes of
standardization and regulation. One of us
has argued elsewhere that this is indeed the
case, insofar as the direct interaction of biol-
ogy and medicine that has increasingly char-
acterized the evolution of Western
biomedicine sinceWorldWar II has been ac-
companied by a systematic recourse to the
collective production of evidence involving
the establishment of conventions, sometimes
tacit and unintentional, but most often ar-
rived at through concerted programs of ac-
tion [11]. These programs involve the
entities and protocols produced and main-
tained by extended networks of researchers,
clinicians, and industrial actors. ExamplesFigure 1: Growth in the number of microarray publications, patents, and projects.
Since the late 1990’s there has been a steep increase in productivity in all three domains.
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of these range from multi-center cancer clin-
ical trials carried out by cooperative groups
to the production of a standardized nomen-
clature of human leukocyte reagents and the
establishment of predictive cancer genetics
services [12,13,14].
In this paper, we would like to pursue
this line of research by investigating the
standardization and regulation of microar-
rays, a tool that has become emblematic of
post-genomic medicine.After briefly situat-
ing the role of this new technology, we will
examine how its development was predi-
cated upon the establishment of hybrid reg-
ulatory networks that have become
increasingly extended as microarrays reach
a stage where they are now ready to “take
on the clinic.”
MICROARRAYS: A POST-GENOMIC
TOOL OF CHOICE
Microarrays are an emergent technol-
ogy of contemporary biomedicine. A single
DNAmicroarray contains thousands of short
DNA sequences arrayed on a solid surface.
Compared to previous molecular genetic ap-
proaches, a microarray experiment involves
the simultaneous analysis of many hundreds
or thousands of genes as opposed to single
genes, thus making them a key tool of the
post-genomic era. According to a PubMed
search, the number of articles based on mi-
croarray technology has grown exponen-
tially during the last decade, from fewer than
200 in 1999 to more than 6,000 in 2005, for
a total of more than 27,000 articles in six
years. These articles are not confined to ex-
perimental reports, as an increasing number
of publications describe clinical applications
of microarrays [15-19]. A search in the
Computer Retrieval of Information on Sci-
entific Projects (CRISP) database of the
projects funded by the National Institutes of
Health yielded 13,954 awards by the end of
2006. A search in the international patent
database Derwent Innovation Index found
approximately 6,500 patents (see Figure 1)
[20]. On the industrial side, world DNAmi-
croarray revenue was $596 million in 2003
and revenue for the total U.S. DNAmicroar-
ray market was approximately $446.8 mil-
lion in 2005 [21,22]. The 2006 revenues of
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Affymetrix and Illumina, were, respectively,
$355 million and $184 million [23]. In short,
microarray technology is not only growing
rapidly, but it also is being translated simul-
taneously into the scientific, clinical, and
commercial domains.
In their “Strategic Analysis of World
DNAMicroarray Markets,” the authors of a
Frost & Sullivan report predict that the ac-
ceptance of microarrays as diagnostic tools
will be contingent on the manufacturers’
ability to overcome “laboratory-to-
laboratory and platform-to-platform incon-
sistencies” [22].This clearly understates the
issue, and we argue here that standardization
of the many different elements that partake
in a microarray experiment do not simply re-
late to the diagnostic use of the technology
but more broadly to the shared acceptance
of the technology as a reliable tool for pro-
ducing genomic findings.
THE BEGINNINGS OF
MICROARRAYS
As is most often the case with scientific
instruments and technologies, especially
those that resort in part to pre-existing tech-
niques, it is difficult to establish an exact and
uncontroversial origin for microarray tech-
nology. Several groups and people claim to
have played a role in its development, and
we can follow the somewhat meandering,
technical, and scientific lineage of microar-
rays by examining publication routes and
patent applications.The microarray is an ex-
ample of a scientific instrument that has
been produced through networks of collab-
oration, and as we will see, microarray tech-
nology cannot be reduced to its instrumental
parts.The tool only acquires its full meaning
once it is related to specific bodies of knowl-
edge (in the present case, molecular genet-
ics) and connected to specific sets of issues.
As noted by Baird, the question of knowing
whether a scientific instrument works is in-
timately related to the question of knowing
how it works [1].The point is that in order to
produce meaningful scientific results, a tool
must be entrenched in an evidential context,
i.e., a network of scientific questions, enti-
ties, and issues as well as laboratory and
clinical routines for which its use is deemed
relevant.
When DNA microarrays emerged on
the public scientific scene in the early 1990s,
only a very limited number of actual biolog-
ical experiments had been carried out. The
technology was still a tool looking for a
problem to which it could be applied. Work
on early prototypes of microarray instru-
mentation was under way by the late 1980s,
namely within a team led by Stephen Fodor
of theAffymax Research Institute and future
president of Affymetrix, currently the lead-
ing manufacturer of microarrays and related
equipment.Apaper by Fodor and colleagues
entitled “Light-directed, spatially address-
able parallel chemical synthesis” appeared
in the February 15, 1991, issue of Science
outlining a new technique that combined el-
ements from the semiconductor industry and
combinatorial chemistry [24]. The authors
mentioned that the new technique could be
of use in the discovery of principles behind
molecular interactions, but the article was
primarily one introducing a new technique,
rather than a scientific article reporting the
results of a biological experiment. More-
over, observers have argued that rather than
inventing a new technique from scratch, the
authors succeeded in miniaturizing pre-ex-
isting technologies. Some noted that
macroarrays were a precursor to microar-
rays, which have now in turn led to protein
arrays [25].Although these are distinct tech-
nologies in themselves, they move on the
same trajectory to scientific discovery [26].
Between 1992 and 1995, Fodor and col-
leagues published several more articles fo-
cusing on methods for sequencing DNA. In
September 1995, members of Affymetrix
published yet another article that presented
the company’s products as standardized
tools, in contrast to the “homemade” arrays
produced by individual laboratories:
The collection of data forms an
“image” of the array. Image processing
software, GeneChip software
(Affymetrix, Santa Clara, CA, USA),
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thesis sites and integrate the data over
each synthesis site. A robust benchtop
version of this detection instrument,
the GeneChip scanner (Affymetrix)
has been developed. [27]
Affymetrix, however, was not the only
player in the field of microarray technology.
The company’s “engineering” approach to
microarray production involved the use of
photolithographic methods to synthesize
hundreds of thousand of oligonucleotides on
a small glass surface, but an alternative, less
“industrial” approach was available. Devel-
oped in the early 1990s by Patrick Brown’s
team at Stanford University, this more dis-
tinctively biological technique used a robot
to deposit cDNA spots onto a coated glass
slide [28].
A month after the Affymetrix article
praising its “GeneChip” technology, the
Stanford University team published a
widely cited Science article (3,327 citations
by September 2007, according to the Web
of Science) often mentioned as the first pub-
lished paper to report actual biomedical re-
sults based on parallel microarray analysis.
Entitled “Quantitative Monitoring of Gene
Expression Patterns with a Complementary
DNAMicroarray” [29], and using the “spot-
ted microarray” approach, the paper com-
pared gene expression in the root and leaf
tissue of a weed called Arabidopsis thaliana
(a model organism for molecular genetics).
The weed itself was used more as a “proof
of concept” than as an end in itself, for the
article ended on a “promissory note” men-
tioning the advent of personalized medi-
cine:
A wide variety of acute and
chronic physiological and pathological
conditions might lead to characteristic
changes in the patterns of gene expres-
sion in peripheral blood cells or other
easily sampled tissues. In concert with
cDNAmicroarraysformonitoringcom-
plex expression patterns, these tissues
might therefore serve as sensitive in
vivo sensors for clinical diagnosis. Mi-
croarrays of cDNAs could thus provide
a useful link between human gene se-
quences and clinical medicine. [29]
Speculations concerning the use-value
of a technology contribute to the shaping of
its future directions [30]. While it is now
widely accepted that DNA microarrays are
useful for detecting genes expressed in dis-
eases and this kind of information eventually
may inform medical treatment [31], this was
not necessarily the case at the time. The
Schena et al. article was strategically placed
in a Science “Genome Issue” that contained
a report proudly announcing that we were
“Entering a Postgenome Era” and hailing
microarray experimentation as a break-
through [32].That same report, however, si-
multaneously warned of the mess ahead in
sorting out gene expressions and cited a
Johns Hopkins scientist as saying “we are
now going to have expression maps of
100,000 different genes. Good luck figuring
that out!” [32]This was one of the first pub-
lic mentions of an impending need to tame
the avalanche of unstandardized data ex-
pected to emerge from an increasing number
of laboratories as the new technique became
widely adopted.
A THREATENING FLOOD OF DATA
In the early 1990s, when the first tech-
nical articles on microarrays appeared, no
major concerns were expressed about the
possibility of analyzing, validating, and
comparing data emerging from the use of the
novel technique.The situation changed after
1995, as soon as the scientific meaning of
the new tool began to take shape. Following
the publication of the Schena et al. article
and the subsequent publication of a 1996 ar-
ticle resulting from the collaboration of the
Stanford team with a NIH team, focusing
this time on human cancer genes [33], sci-
entific journals increasingly began to won-
der about the many parameters involved in
interpreting a microarray experiment, as
well as the lack of global comparability of
results [34,35,36]. In 1998, one of the lead-
ers of this rapidly evolving field, David Bot-
stein, commented in an editorial that “[w]hat1This paragraph is based on field-work observations made onApril 8-9, 2006, at an “Exploratory transcrip-
tomics workshop” hosted by the Réseau québécois de bio-informatique (BioneQ) and sponsored by Genome
Québec, Université du Québec à Montréal, and Université de Montréal.
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began as a trickle of such data now threatens
to be a flood; yet for even the most impor-
tant results, all that most of us have ever
seen are sets of stills or collapsed flat repre-
sentations.” [37]
In 2002, the NIH had begun funding the
Toxicogenomics Research Consortium, a
group of seven research centers with the
goal of assessing the causes of gene expres-
sion variation across labs [35]. Many ques-
tions were being raised: How was anyone to
know whether the different platforms being
used were comparable or even how they
were implemented? How were statistics cal-
culated? How could anyone assure that the
many uncertainties within each experiment
were leading to reliable results? [38,39]
These concerns did not dampen enthusiasm
for potential microarray applications, but in-
stead incited supporters of the new technol-
ogy to realize the need for standard-building
initiatives in order to solve the problem of
comparability.
At this stage, readers unfamiliar with
microarrays may wonder why it is so diffi-
cult to assess the results obtained with this
technology. Microarray instrumentation
does not produce, strictly speaking, raw data
— as with other recent computerized appa-
ratuses, the readings made by the instrument
are generated and transmitted via several
hardware components, such as photomulti-
pliers, and software programs that imple-
ment statistical calculations and produce
visual representations of the results [40].
Observers of the field routinely note that a
lot of the messiness involved in getting reli-
able, reproducible, and comparable experi-
mental results pertains to the extremely large
data sets produced from a single experiment.
The enormous matrices produced by each
array inevitably contain noise and uncer-
tainty, casting doubts upon the interpretation
of significant results.
Each experiment uses an array similar
to a momentary snapshot or photograph of
gene expression, meaning each photograph
must be interpreted by the observer to a cer-
tain extent.At a recent bioinformatics work-
shop, one of the participants noted that the
first level of quality control is as blunt as
“look at the image!”1 A preliminary glance
at the computerized image — that, once
again, is the result of statistical treatments
— will reveal clusters and spot intensities.
Data are then normalized in order to identify
the possible role of spots, at which time
meaning is extracted from the data structure
in order to explain biological behavior. A
plenitude of statistical devices are employed
throughout the process such as t-tests, K-
means, ANOVA tests, and Euclidean dis-
tance. Workshop participants were told to
use multiple hypothesis testing in order to
lower the number of predicted false posi-
tives, since false positives are a given in mi-
croarray research and lowering their
emergence early on will improve results. In
terms of statistical measures, the choice of a
given statistical device can produce an inter-
estingly random variation in results. The
procedure for generating K-means, for ex-
ample, starts by randomly guessing K-cen-
ters between spots. This process defines
clusters that may or may not have been there
to begin with but provides a good estimate
of where they might be if they are lurking in
the data matrix. The (unpublished) work-
book distributed during the workshop re-
minded participants that “the outcome
depends on the initial guesses,” thus making
the point that they would most likely not en-
counter “actual clusters” but instead statis-
tically produced estimates of clustering.
Atop NCI statistician recently objected
to the claim that the main problem for mi-
croarray research lies in the massive datasets
generated by each experiment: “[Myth]:
That the greatest challenge is managing the
mass of microarray data. … [Truth]: Biolo-
gists need both good analysis tools and good
statistical collaborators. Both are in short
supply.” [41]Although he also extended his
criticism to the systematic resort to complexRogers and Cambrosio: The standardization of microarrays 171
classification algorithms such as neural net-
works and to techniques such as data mining
and pattern recognition, the fact remains that
the emergence of the new specialty known
as bioinformatics — whose practitioners are
skilled users of these techniques — has ac-
companied the growth of microarrays.
While a discussion of the development of
this specialty goes beyond the limits of this
article, it should be noted that, as maintained
by sociologists of science and technology, in
order to follow the trajectory of an instru-
ment or a technique one has to analyze it as
part of a growing network of related tools,
artifacts, skills, institutions, and people that
in the present case include bioinformatics as
a new domain of activity [42]. In turn, by be-
coming part of existing networks, such as
cancer research, a novel technology such as
microarrays contributes to the reconfigura-
tion of biomedical activities. In particular,
problems concerning the results produced
by microarrays do not only concern the hap-
less technicians working with them and do
not stop at the laboratory’s doors, as data
variability poses a further challenge to ge-
nomic research initiatives built on the prem-
ise that data produced in different settings
are comparable.To achieve comparability, a
multi-tiered process involving industrial, ac-
ademic, and government actors had to be put
in place.
MGED: GRASSROOTS PRACTICES
FOR STANDARDS
As shown by Figure 1, by the late 1990s
the number of publications reporting mi-
croarray experiments was on the rise, yet
this growth also was marked by fears the
technology was developing more quickly
than the community could understand it.The
field of genomics already provided multiple
examples of “bottom-up” initiatives, such as
research networks and consortia designed to
tackle specific problems (e.g., sequencing a
given chromosome), as well as more formal
organizations such as the Human Genome
Organization (HUGO). Moreover, problems
raised by the uncontrolled growth of new
biomedical technologies, such as that of
monoclonal antibodies, had been solved in
the past by resorting to distributed regula-
tory networks [43]. Given these departures,
when a group at the European Bioinformat-
ics Institute (EBI) decided in the late 1990s
to take it upon themselves to launch an ini-
tiative that would bring scientists closer to
understanding and comparing microarray
data, the move was not completely unex-
pected.
The EBI group ideally was situated for
heading this movement, as it already consti-
tuted a leading bioinformatics cluster well
positioned within the genomic discovery
network. EBI is a satellite station of the Eu-
ropean Molecular Biology Laboratory
(EMBL) and closely affiliated with theWell-
come Trust Sanger Institute, a central insti-
tution in the Human Genome Project. The
head of the microarray group,Alvis Brazma,
worked to assemble a task force for the cre-
ation and dissemination of microarray stan-
dards. His task certainly was facilitated by
the fact that the field itself was characterized
by the presence of a fairly limited set of
highly visible industrial and academic ac-
tors. On the industrial side, we already men-
tioned the leading role played by
Affymetrix. On the academic side, a recent
search in the Web of Science showed that
two researchers — Patrick Brown and David
Botstein, both from Stanford — dominate
the field in terms of the number of publica-
tions (116 and 77, respectively) and the
number of citations received (31,793 and
21,524, respectively; one of their joint pa-
pers has received 4,231 citations). More-
over, 17 of Brown’s papers and 15 of
Botstein’s figure among the top 0.01 percent
most cited papers in their domain. Authors
further down the list also demonstrate a
strong performance in terms of these same
parameters. A co-authorship network of the
most cited authors in the field (not shown
here) [20] indicates these authors occupy a
strategic “bridge” position between the main
clusters of co-authors.
Before long, the EBI group joined
forces withAffymetrix and Stanford Univer-
sity, the dominant players in microarray ex-
perimentation, to establish a self-styled2The five working groups were: a) Experiment description and data representation standards; b) Microarray data
XML exchange format; c) Ontologies for sample description; d) Normalization, quality control and cross-plat-
form comparison; and e) Future user group: queries, query language, data mining.
3This event was extended to both academic and industry participants, and was sponsored by Incyte Genomics,
GeneLogic, and GlaxoWellcome.
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grassroots movement called the Microarray
Gene Data Expression Society (MGED)
with a basic aim to standardize the field.
From the very outset, MGED was a “hy-
brid” organization, as it included industrial
and university members. EBI, while offi-
cially a public institution, is itself a “hybrid”
organization in the sense that, as convinc-
ingly argued by McMeekin and Harvey, its
operations are predicated upon the existence
of knowledge flows between interdependent
public/private databases [44]. In spite of its
“grassroots” status, MGED’s legitimacy was
grounded in a solid infrastructure, allowing
it to move forward swiftly with plans for
standard-setting.
MGED officially was founded in No-
vember 1999 at an EBI meeting, now known
as MGED1, a brief, two-day event, with the
stated goal of putting an end to the messi-
ness of microarray experimentation by es-
tablishing data communication standards
ensuring the reproducibility and, thus, the
reliability of results.Aminimum of informa-
tion, it contended, was absolutely necessary
in order to effectively communicate the
meaning of results. Fittingly, the standards
sought by the organization were called
“Minimum InformationAbout a Microarray
Experiment” (MIAME) [45]. InApril 2001,
with MIAME nearly eight months from its
official completion, an article in Science fur-
ther discussed the problem of comparability
between experiments and proudly an-
nounced that data standards were on the
horizon [46]. In addition to enthusiastically
welcoming the coming of standards, the ar-
ticle mentioned that the “putting aside of
egos” in the quest for a common standard
was essential to the process.The implication
here was that one needed to address the dif-
fering needs and concerns of the several cat-
egories of people involved in microarray
experiments, pointing once again to the fact
that a coordination (rather than a division)
of labor underlies this line of work.
In February 2000, MGED-related EBI
scientists called attention to the problem of
the existence of many public and private
data repositories that lacked compatibility
[47].As a possible solution to this quandary,
the article announced that “[m]eanwhile, the
EBI, in collaboration with the German Can-
cer Research Centre, is developingArrayEx-
press, a gene-expression database compliant
with the current recommendations.” [47] By
interlinking standards and the repository, as-
surance could be given that minimum stan-
dards would be met by all of the datasets
deposited. One of the outcomes of MGED1
had been the establishment of five working
groups on such issues as dataset compatibil-
ity2. As planned, the five groups assembled
at the European Molecular Biology Labora-
tory (EMBL) in Heidelberg, Germany in
May 2000 for MGED2.The goal of that sec-
ond meeting was to finalize recommenda-
tions for MIAME through a synthesis of
results received from the five task groups3.
The number of participants was restricted to
250, and they were able to agree upon stan-
dards for annotation, storage, and commu-
nication of microarray data. MGED3 took
place in March 2001 at Stanford, by which
time a paper describing MIAME was almost
ready. It was published in the December
2001 issue of Nature Genetics [45] and
called for the deposition of experiment in-
formation into public data repositories but
did not insist on specific ones.
In June 2002, the MGED Society be-
came a not-for-profit organization, and by
October 2002, it had managed to convince a
number of key scientific journals such as
Nature, Cell, and The Lancet to require
MIAME for publication of microarray re-
sults.As stated in an open letter to scientific
journals requesting formal compliance with
the MIAME standards:
For microarray experiments, sim-
ply defining the appropriate data has4At the time, the two main repositories were GEO, overseen by the National Center for Biotechnology Informa-
tion (NCBI) (www.ncbi.nlm.gov/geo/), andArrayExpress, overseen by the European Bioinformatics Institute
(EBI) (www.ebi.ac.uk/arrayexpress).
Figure 2: Microarray standards co-authorship network. The map was produced using
ReseauLu, a software package for heterogeneous network analysis (www.aguidel.com).
We queried PubMed for microarray articles, using the subheading “standards” (1991-pre-
sent). The size of the nodes is proportional to the number of articles co-authored. Only the
top 150 authors are represented on the map, and each author is represented by a single
node.
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been a challenge, because the large
quantity of data generated in each ex-
periment and the typical complexity of
the ancillary information needed to in-
terpret the results are unlike anything
that has yet faced the biological re-
search community. [48]
In addition to enforcing publication
standards, MGED requested that primary
experimental data be deposited into a per-
manent public data repository4. Their re-
quest was largely successful, mostly because
many journal committees already were
searching for experiment standards to aid
them in the selection of “good scientific
work” buried within the growing amount of
microarray submissions. A Nature editorial
expressed relief that they could “at last” en-
force microarray standards [49]. The same
editorial went on to explain how frustrating
it had been to review microarray papers in
the absence of standardized experimental
details that would allow referees to assess
the reliability of reported results. Interim,
homemade solutions to this issue had proved
problematic; for instance: “[m]any journals
allowed authors to put the huge data files on
their own websites for the review process,
until it became clear that unscrupulous au-
thors compromised the anonymity of refer-
ees by tracking who had visited their
website.” [49] By enforcing the MIAME re-
quirements, journals could rest assured they
were overcoming these problems: “[h]arriedRogers and Cambrosio: The standardization of microarrays 174
editors can rejoice that, at last, the commu-
nity is taming the unruly beast that is mi-
croarray information.”[49]
From MGED3 onward, the meetings
drew hundreds of participants as its interna-
tional scope widened. MGED4 took place
again in the United States, but MGED5-8
took place in Japan, France, Canada, and
Norway. In 2006, MGED9 returned to the
United States (Seattle) and drew more than
200 participants. Figure 2 shows a co-au-
thorship map of publications concerning mi-
croarray standards.The cluster at the bottom
right of the map consists mostly of MGED
authors with the previously mentionedAlvis
Brazma at its center, while the cluster above
it predominantly includes representatives
from industry and the FDA, with notable ac-
ademic representation from Stanford and
Johns Hopkins. The map shows the exis-
tence of a close international collaboration
between academic scientists in biostatistics
and computer science that in turn entwines
government/industrial actors. The role of a
“bridge” between the two highlighted clus-
ters is played mainly by Helen Causton
(MRC Clinical Sciences Centre, Imperial
College, London) and, to a minor extent, by
John Quackenbush (Dana-Farber Cancer In-
stitute, Boston) and Irene Kim (Johns Hop-
kins School of Medicine). Thus, as is
generally the case within the field, microar-
ray standardization processes result from the
concerted action of a relatively small num-
ber of actors whose cooperative endeavor
cuts across government, academic, and in-
dustrial boundaries.
CRITICISMS OF STANDARDS (CAN
THEY PLEASE EVERYONE?)
Microarray standards must simultane-
ously appeal to biologists, computer scien-
tists (bioinformatics specialists), and
statisticians (and, of course, industrial ac-
tors). However, these different groups do not
necessarily share a consensus concerning the
definition of what should count as “reliable”
or “reproducible.” Biologists generally insist
on observable facts, while statisticians pro-
duce a different type of fact through statisti-
cal manipulation; as for bioinformaticians
and computer science specialists, their ac-
tivities focus on database inputs and outputs.
While, in principle, these different elements
should be aligned to achieve a successful
microarray experiment, tensions remain,
turning the task of establishing mutually ac-
ceptable data standards into a difficult chal-
lenge.The standardization movement, as we
have seen, began at EBI and thus can be said
to have been propelled primarily by bioin-
formaticians who worry about reliable data-
bases. Resistance to these standards often
comes from laboratory biologists who are
hesitant to invest financial resources in order
to follow stricter experimental standards.
Undoubtedly, keeping the cost of a single
microarray experiment down means that one
can perform more experiments.This issue is
acknowledged in the first description of
MIAME that evoked potential financial
commitments from its users:
Storing the primary image files
would require a significant quantity of
disk space, and there is no community
consensus as to whether this would be
cost-effective or whether this should be
the task of public repositories or the
primary authors [45].
The creation of public repositories soon
provided a solution, but in addition to being
expensive, standard enforcement could be
time-consuming. MIAME authors were
aware they would have to sell their initiative
to a community that was likely to receive it
with mixed feelings. On the one hand, stan-
dards were needed in order to produce scien-
tifically meaningful results. On the other
hand, they could potentially become a hin-
drance for this fast-developing field. Aware
of these criticisms, MIAME attempted to ne-
gotiate a compromise between finely de-
tailed annotation and a lack of information:
Too much detail may be too tax-
ing for data producers and may com-
plicate data recording and database
submission, whereas too little detail
may limit the usefulness of the data.5These statements are taken from an interview with two biologists at EMBL,August 2006.
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MIAME is an informal specification,
the goal of which is to guide coopera-
tive data providers. It is not designed
to close all possible loopholes in data
submission requirements [45].
While some biologists continued to al-
lege that MIAME was a resource-consum-
ing endeavor with little payback for them in
the end, others made a more conceptual crit-
icism, arguing it was time to go beyond stan-
dards because replication and consistency do
not say enough about experimental out-
comes: “[c]onsistent standards between lab-
oratories would help improve the
consistency of results — but consistency is
not enough — after all the results within a
laboratory were all consistent but the results
can be consistently wrong.” [50] Yet other
biologists contend that despite MGED’s as-
sertion it is a grassroots organization, the
standards are being dictated from the top
down, by bioinformaticians who primarily
deal with experimental end points and want
to impose their vision upon the biologists
who do all of the experimental work from
its inception to lab bench conclusion5.
MIAME IS NOT ENOUGH: THE PRO-
LIFERATION OF STANDARDS
Today,MGEDoverseesfiveworkgroups
in addition to MIAME: MAGE (Microarray
and Gene Expression), MISFISHIE (Mini-
mum Information Specification For In Situ
Hybridization and Immunohistochemistry
Experiments), OWG (Ontology workgroup),
RSBI WGs (Reporting Structure for Biolog-
ical Investigations Working Groups), and
Transformations. MIAME, in other words,
was only the starting point of a motley of
standardization initiatives that now include
several additional aspects of microarray ex-
perimental work and also extend to other
types of genomic and proteomic experimen-
tation [51,52,53,54]. For instance, MAGE,
oneofavarietyofopen-sourceprojects,con-
tains different extensions for standardizing
microarrayexpressiondataandsimplifytheir
translationacrossdifferentdatasystems.On-
tologyisanotherkeydomain,sincestandard-
ization now targets, in addition to statistical
aspects,theannotationsusedtoreportresults.
Onceagain,thepurposebehindthisinitiative
is to tame massive amounts of data by using
a classificatory vocabulary that lacks the va-
gariesofnaturallanguage.Severalrelatedini-
tiativestransitdirectlyandindirectlythrough
MGED members. They include groups such
astheGeneOntologyConsortium,whichop-
timisticallyhopestodevelopuniversaltermi-
nology for the global genomics community:
Ontologies have long been used
in an attempt to describe all entities
within an area of reality and all rela-
tionships between those entities. An
ontology comprises a set of well-de-
fined terms with well-defined relation-
ships. The structure itself reflects the
current representation of biological
knowledge as well as serving as a
guide for organizing new data [55].
Ontologies contain controlled vocabu-
laries that are expected to permit the transla-
tion of microarray data across and within
scientific domains. Since, however, ontolo-
gies are never complete, they are ongoing
projects that require continual revisions and
additions from those working closely with
the technology and its results.
Allofthestandardizationinitiativesmen-
tioned in the previous paragraph bear the im-
print of bioinformatics. As a new discipline,
bioinformaticsisstillridingthewaveofmajor
initiativessuchastheHumanGenomeProject
andtheHapMapProjectandisnegotiatingits
ownscientificidentitybydefiningworkprac-
ticesandtrainingprograms.Atthesametime,
itmustcontendwiththeothercommunitiesof
practice that have a stake in the development
of microarrays, including biology, statistics,
genetics,toxicology,pharmacogenomics,and
cancer research.The introduction of microar-
rays in the clinic has further transformed the
field, mobilizing new actors and adding tar-
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FDA, for instance, recently sponsored a Mi-
croArrayQualityControl(MAQC)projectin
order to examine the contentious issue of
inter-platform reproducibility of microarray
experiments[56].MAQC,inotherwords,dif-
fers from MGED insofar as it tackles the po-
tentiallymorethornyissuesofdatageneration
and validity, thus directly confronting the
messiness of experimental work. The project
involved 137 participants from 51 organiza-
tions who were asked to compare seven dif-
ferent microarray platforms. Results were
qualified as promising, but there was still
more comparability among certain platforms
than others, and as with all microarray exper-
iments, no two experiments were entirely
identical. Irrespective of these results, the in-
teresting issue from a social science point of
view lies in the fact that in order to confront
this new technology, standard-setting initia-
tives must not only proliferate, but also have
to experiment with novel regulatory ap-
proaches that mobilize extended networks of
researchandindustrialorganizations.Inother
words,assciencestudiesscholars,wewitness
the co-production of a technology and the
arrangements (social, technical, institutional,
andmaterial)thatshapeitstrajectory[57,58].
While this is not the place to examine the
complexissueoftheburgeoningstandardiza-
tionofmicroarraysasclinicaltools,weshould
notethatasimilarconclusionapplies.Asingle
example will suffice: By examining, at once,
thousands of genes, one can in principle
tremendously reduce the time previously al-
lotted to the task of molecular investigations.
One of the predicted results is that this will
allow the conflation of diagnosis and therapy
(arguably, on an individualized basis), a
process for which a name has already been
found: theranostics [59,60]. Diagnosis and
therapy are distinct medical and regulatory
categories.Iftheranosticssucceeds,regulators
and the standard-setting specialists on whom
they rely will have to go back to the drawing
board.
CONCLUSION
Despite debate and controversy, the
MGED Society has consistently maintained
that the applicationof MIAME, MAGE, and
related products can, and should, at least in
theory, lead to increased comparability and
reproducibilityamongreportedexperiments.
Associalscientists,weareinterestedinstan-
dard-setting initiatives such as the ones pro-
pelled by MGED because they exemplify
newformsofcollaborativeworkamongbio-
medicalresearchers,computerscientists,and
statisticians from public, industrial, and, in-
creasingly, hybrid research organizations.
Thegoaloftheseendeavorsistoproducethe
conventions that increasingly regulate bio-
medical work. By using the term “conven-
tions,” we do not mean they are entirely
arbitrary,fortheyaregroundedinthetechni-
cal and experimental infrastructure of the
field, but they are to a large extent the result
of negotiations and compromise. Indeed, as
we have seen, collaborative work does not
exclude controversy, and in this article we
discussed some of the fault lines that have
appeared in this respect within the microar-
ray community.
MIAME and its fellow standards are
certainly an important achievement. The
original version of MIAME has been up-
dated several times, allowing for more de-
tailedspecificationsofthesoftwareandtools
which support it as well as for more precise
experimental descriptions . Many practition-
ers, however, still feel as though there is a
long way to go in the way of comparability
of results between labs.As prices of individ-
ual chips are expected to continue to fall
[61], microarray experiments are likely to
proliferate, thus making the task of finding a
solutiontothecomparabilityissueevenmore
urgent. Moreover, increasing resort to mi-
croarrays for human diagnostic purposes
[62] adds a distinctively clinical dimension
to the regulatory conundrum [15,63,64]. In
short, microarray technology provides a fas-
cinating case studyofhowsocial institutions
(research organizations, biotech companies,
regulatory agencies) choose standards and
how, in turn, standards produce new social
and scientific institutions [65].
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